Cargando…

Algorithm to improve the diagnosis of paraneoplastic neurological syndromes associated with SOX1 antibodies

SOX1 antibodies (SOX1-abs) are associated with paraneoplastic neurological syndromes (PNS) and small cell lung cancer (SCLC). In many clinical laboratories SOX1-abs are determined by commercial line blots without confirmation by cell-based assay (CBA) with HEK293 cells expressing SOX1. However, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Arnaldos-Pérez, Cristina, Vilaseca, Andreu, Naranjo, Laura, Sabater, Lidia, Dalmau, Josep, Ruiz-García, Raquel, Graus, Francesc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191251/
https://www.ncbi.nlm.nih.gov/pubmed/37207233
http://dx.doi.org/10.3389/fimmu.2023.1173484
_version_ 1785043423176163328
author Arnaldos-Pérez, Cristina
Vilaseca, Andreu
Naranjo, Laura
Sabater, Lidia
Dalmau, Josep
Ruiz-García, Raquel
Graus, Francesc
author_facet Arnaldos-Pérez, Cristina
Vilaseca, Andreu
Naranjo, Laura
Sabater, Lidia
Dalmau, Josep
Ruiz-García, Raquel
Graus, Francesc
author_sort Arnaldos-Pérez, Cristina
collection PubMed
description SOX1 antibodies (SOX1-abs) are associated with paraneoplastic neurological syndromes (PNS) and small cell lung cancer (SCLC). In many clinical laboratories SOX1-abs are determined by commercial line blots without confirmation by cell-based assay (CBA) with HEK293 cells expressing SOX1. However, the diagnostic yield of commercial line blots is low and the accessibility to the CBA, that is not commercially available, limited. Here, we evaluated if the addition of the band intensity data of the line blot and the immunoreactivity in a tissue-based assay (TBA) improve the diagnostic performance of the line blot. We examined serum of 34 consecutive patients with adequate clinical information that tested positive for SOX1-abs in a commercial line blot. Samples were also assessed by TBA and CBA. SOX1-abs were confirmed by CBA in 17 (50%) patients, all (100%) had lung cancer (SCLC in 16) and 15/17 (88%) had a PNS. In the remaining 17 patients the CBA was negative and none had PNS associated with lung cancer. TBA was assessable in 30/34 patients and SOX1-abs reactivity was detected in 15/17 (88%) with positive and in 0/13 (0%) with negative CBA. Only 2 (13%) of the 15 TBA-negative patients were CBA-positive. The frequency of TBA-negative but CBA-positive increased from 10% (1/10) when the band intensity of the line blot was weak to 20% (1/5) in patients with a moderate or strong intensity band. Confirmation by CBA should be mandatory for samples (56% in this series) not assessable (4/34; 12%) or negative in the TBA (15/34; 44%).
format Online
Article
Text
id pubmed-10191251
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101912512023-05-18 Algorithm to improve the diagnosis of paraneoplastic neurological syndromes associated with SOX1 antibodies Arnaldos-Pérez, Cristina Vilaseca, Andreu Naranjo, Laura Sabater, Lidia Dalmau, Josep Ruiz-García, Raquel Graus, Francesc Front Immunol Immunology SOX1 antibodies (SOX1-abs) are associated with paraneoplastic neurological syndromes (PNS) and small cell lung cancer (SCLC). In many clinical laboratories SOX1-abs are determined by commercial line blots without confirmation by cell-based assay (CBA) with HEK293 cells expressing SOX1. However, the diagnostic yield of commercial line blots is low and the accessibility to the CBA, that is not commercially available, limited. Here, we evaluated if the addition of the band intensity data of the line blot and the immunoreactivity in a tissue-based assay (TBA) improve the diagnostic performance of the line blot. We examined serum of 34 consecutive patients with adequate clinical information that tested positive for SOX1-abs in a commercial line blot. Samples were also assessed by TBA and CBA. SOX1-abs were confirmed by CBA in 17 (50%) patients, all (100%) had lung cancer (SCLC in 16) and 15/17 (88%) had a PNS. In the remaining 17 patients the CBA was negative and none had PNS associated with lung cancer. TBA was assessable in 30/34 patients and SOX1-abs reactivity was detected in 15/17 (88%) with positive and in 0/13 (0%) with negative CBA. Only 2 (13%) of the 15 TBA-negative patients were CBA-positive. The frequency of TBA-negative but CBA-positive increased from 10% (1/10) when the band intensity of the line blot was weak to 20% (1/5) in patients with a moderate or strong intensity band. Confirmation by CBA should be mandatory for samples (56% in this series) not assessable (4/34; 12%) or negative in the TBA (15/34; 44%). Frontiers Media S.A. 2023-05-03 /pmc/articles/PMC10191251/ /pubmed/37207233 http://dx.doi.org/10.3389/fimmu.2023.1173484 Text en Copyright © 2023 Arnaldos-Pérez, Vilaseca, Naranjo, Sabater, Dalmau, Ruiz-García and Graus https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Arnaldos-Pérez, Cristina
Vilaseca, Andreu
Naranjo, Laura
Sabater, Lidia
Dalmau, Josep
Ruiz-García, Raquel
Graus, Francesc
Algorithm to improve the diagnosis of paraneoplastic neurological syndromes associated with SOX1 antibodies
title Algorithm to improve the diagnosis of paraneoplastic neurological syndromes associated with SOX1 antibodies
title_full Algorithm to improve the diagnosis of paraneoplastic neurological syndromes associated with SOX1 antibodies
title_fullStr Algorithm to improve the diagnosis of paraneoplastic neurological syndromes associated with SOX1 antibodies
title_full_unstemmed Algorithm to improve the diagnosis of paraneoplastic neurological syndromes associated with SOX1 antibodies
title_short Algorithm to improve the diagnosis of paraneoplastic neurological syndromes associated with SOX1 antibodies
title_sort algorithm to improve the diagnosis of paraneoplastic neurological syndromes associated with sox1 antibodies
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191251/
https://www.ncbi.nlm.nih.gov/pubmed/37207233
http://dx.doi.org/10.3389/fimmu.2023.1173484
work_keys_str_mv AT arnaldosperezcristina algorithmtoimprovethediagnosisofparaneoplasticneurologicalsyndromesassociatedwithsox1antibodies
AT vilasecaandreu algorithmtoimprovethediagnosisofparaneoplasticneurologicalsyndromesassociatedwithsox1antibodies
AT naranjolaura algorithmtoimprovethediagnosisofparaneoplasticneurologicalsyndromesassociatedwithsox1antibodies
AT sabaterlidia algorithmtoimprovethediagnosisofparaneoplasticneurologicalsyndromesassociatedwithsox1antibodies
AT dalmaujosep algorithmtoimprovethediagnosisofparaneoplasticneurologicalsyndromesassociatedwithsox1antibodies
AT ruizgarciaraquel algorithmtoimprovethediagnosisofparaneoplasticneurologicalsyndromesassociatedwithsox1antibodies
AT grausfrancesc algorithmtoimprovethediagnosisofparaneoplasticneurologicalsyndromesassociatedwithsox1antibodies